@Article{,
AUTHOR = {Paul R. Gittens, Costas D. Lallas, Mark L. Pe, Robert Perkel, Christine Folia, Leonard G. Gomella},
TITLE = {Uropharmacology for the primary care physician},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {15},
YEAR = {2008},
NUMBER = {Suppl.4},
PAGES = {78--91},
URL = {http://www.techscience.com/CJU/v15nSuppl.4/63118},
ISSN = {1488-5581},
ABSTRACT = {Advances in the understanding of the pathophysiology 
of a variety of urological disorders have resulted in the 
development of novel medications to manage these diseases. 
While many disorders such as erectile dysfunction, 
overactive bladder, hypogonadism and benign prostatic 
hypertrophy have traditionally been managed primarily by 
urologists, the use of these newer medications has become 
commonplace in the primary care setting. For example, 
symptomatic benign prostatic hyperplasia therapy, while 
historically treated with primary surgical intervention, is 
now commonly initially managed with medical therapy. 
Prostate cancer patients are being treated with newer 
formulations of long term hormone therapy that range 
from monthly to yearly administration. Additionally, the 
open dialogue about erectile dysfunction can be directly 
traced to the development of oral therapy for this condition. 
Testosterone replacement therapy can be administered 
using a variety of oral, transdermal and intramuscular 
therapies in order to minimize side effects and provide a 
more consistent dosing pattern. Finally, overactive bladder, 
which is a signifi cant problem socially, has many new 
medications available for its treatment. This article will 
review some of the newer classes of urological medications, 
provide an understanding of basic uropharmacology that 
may guide treatment recommendations, and provide insight 
into the potential adverse side effects and interactions of 
these useful medications.},
DOI = {}
}